Hippocampal-sparing radiation for lung cancer patients
Neuropsychological and Oncological Outcomes After Hippocampal-Sparing Prophylactic Cranial Irradiation in Postoperative Patients With Pathologically Nodal Positive Non-Small-Cell Lung Cancer - A Prospective Follow-up Study
This study tests a new type of radiation therapy for lung cancer patients to see if it can prevent brain cancer while protecting their memory.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Taoyuan) |
| Trial ID | NCT02448992 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of hippocampal-sparing prophylactic cranial irradiation (PCI) in patients with pathologically nodal positive non-small-cell lung cancer (NSCLC) who have undergone aggressive treatment. The aim is to reduce the incidence of brain metastasis while minimizing neurocognitive decline associated with traditional whole brain radiotherapy. Participants will receive targeted radiation therapy designed to protect the hippocampus, which is crucial for memory function. The study will assess neurobehavioral outcomes and cognitive functions in these patients.
Who should consider this trial
Good fit: Ideal candidates are adult patients with NSCLC who have undergone definitive surgery and have pathologically confirmed nodal metastasis.
Not a fit: Patients with prior cranial irradiation or those with active primary cancers other than specified exceptions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the risk of brain metastasis in lung cancer patients while preserving cognitive function.
How similar studies have performed: While prophylactic cranial irradiation has been studied in various contexts, this specific hippocampal-sparing approach is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of NSCLC * Must be adult patients (≥ 18 years old) who have received definitive surgery and have a permanent pathology of nodal metastasis * Platinum-based chemotherapy is mandatory * Good performance status better than Eastern Cooperative Group (ECOG) of 2 or a general status of Karnofsky (KPS) \> 70 % * Should have sufficient proficiency in Mandarin language Exclusion Criteria: * Have received prior cranial irradiation * Presence of other active primary cancer (exception of basal cell carcinoma of skin and cervical carcinoma in situ) * Radiographic evidence of brain metastasis/metastases * Clinical evidence of extracranial metastatic disease * Hypersensitivity to magnetic resonance (MR) contrast enhancer * Serious medical or psychiatric illness
Where this trial is running
Taoyuan
- Chang Gung Memorial Hospital — Taoyuan, Taiwan (Recruiting)
Study contacts
- Principal investigator: Chi-Cheng Yang, Ph.D. — Chang Gung University
- Study coordinator: Chi-Cheng Yang, Ph.D.
- Email: ccyang@mail.cgu.edu.tw
- Phone: 886-988378478
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.